KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $6.50.

KRMD has been the subject of a number of analyst reports. B. Riley Financial raised their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Craig Hallum reissued a “buy” rating and issued a $7.00 target price on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Lake Street Capital lifted their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Wall Street Zen lowered KORU Medical Systems from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th.

KORU Medical Systems Price Performance

Shares of KRMD traded down $0.16 on Friday, reaching $4.20. 11,689 shares of the stock traded hands, compared to its average volume of 192,321. The firm has a market cap of $194.75 million, a price-to-earnings ratio of -70.00 and a beta of 0.47. KORU Medical Systems has a 12 month low of $1.86 and a 12 month high of $6.61. The stock’s 50-day moving average price is $4.86 and its 200-day moving average price is $4.81.

KORU Medical Systems (NASDAQ:KRMD) last issued its earnings results on Thursday, March 12th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $10.90 million. KORU Medical Systems had a negative return on equity of 15.90% and a negative net margin of 6.41%. As a group, equities research analysts forecast that KORU Medical Systems will post -0.13 earnings per share for the current fiscal year.

Institutional Trading of KORU Medical Systems

A number of large investors have recently bought and sold shares of the stock. Lakewood Asset Management LLC raised its stake in KORU Medical Systems by 2.8% during the fourth quarter. Lakewood Asset Management LLC now owns 73,945 shares of the company’s stock worth $430,000 after acquiring an additional 2,000 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after purchasing an additional 3,478 shares during the last quarter. Barclays PLC increased its position in shares of KORU Medical Systems by 8.8% during the 4th quarter. Barclays PLC now owns 67,442 shares of the company’s stock worth $392,000 after purchasing an additional 5,457 shares in the last quarter. Invesco Ltd. lifted its holdings in KORU Medical Systems by 24.8% during the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after purchasing an additional 5,546 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in KORU Medical Systems by 26.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock valued at $158,000 after purchasing an additional 5,649 shares during the last quarter. 58.60% of the stock is currently owned by institutional investors.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.